Transurethrale En-bloc-Resektion nicht muskelinvasiver Harnblasenkarzinome

Abstract

Bladder cancer of the urothelium is the second most common malignancy among urological tumors. In view of a worldwide aging population and the fact that increased incidence rates are associated with higher age, new socioeconomic challenges will appear. Even nowadays the treatment of bladder cancer bears the highest lifetime treatment costs per patient among all forms of cancer. In conjunction with higher comorbidity rates among older patients urologists are facing new challenges in the treatment and care of patients with bladder cancer. The standard treatment for non-muscle invasive bladder cancer (NMIBC) is monopolar transurethral resection using resection loops (TURB). Based on experience in the surgical treatment of benign prostatic hyperplasia, different concepts of en bloc resection of bladder tumors using alternative energy resources (e.g. holmium laser, thulium laser and the water-jet HybridKnife) have been developed. Goals of new treatment modalities are reduction of perioperative and postoperative comorbidities, better pathological work-up of the specimens and increased recurrence-free survival. Postulated advantages using laser devices are a more precise cutting line as well as better hemostasis. The evidential value of this review is limited due to the lack of randomized, prospective studies. However, there is a tendency towards a limitation of perioperative and postoperative morbidities as well as higher chance of well-preserved tissues for better pathohistological evaluation using en bloc resection methods. More studies with long-term follow-up periods and better randomization are needed to clarify whether en bloc strategies provide better long-term oncological survival.

Radi̇kal Si̇stektomi̇de İleal Kondui̇t Üri̇ner Di̇versi̇yon İle Konti̇nan Üri̇ner Di̇versi̇yon Uygulanan Hastalarda Yaşam Kali̇tesi̇ni̇n Değerlendi̇ri̇lmesi̇

“…Mesane kanseri üriner sistemi en sık etkileyen ve dünyada yaygın görülen kanserler arasındadır. Ürolojik kanserler arasında en sık ikinci, tüm kanser türleri içinde ise erkelerde 7. sırada, kadınlarda ise 17. sıradadır [1,2]. Mesane kanseri insidansı uluslararası değişimi 14 kata kadar ulaşmaktadır [3].…”